Pfizer released the data regarding the early-stage human trial of a coronavirus pandemic. Pfizer shares jumped 4% on July 1, after the company released this information.
Interestingly, the trial evaluated 45 people. Each person who participated in this trial received 10, 30, or 100 microgram doses of the vaccine or a placebo. Based on the information provided by the company, one of its four coronavirus vaccine candidates produced neutralizing antibodies, which is necessary to build immunity to the virus, in all participants who received two of the 10 or 30 microgram doses after 28 days. It is worth noting that, findings from this trial were posted in a paper released on MedRXiv.
Moreover, after 28 days all participants in the two lower-dose groups had significant levels of binding antibodies.
Pfizer and coronavirus vaccine
The U.S.-based pharmaceutical giant is working with German drugmaker BioNTech. People should take into account that, the companies’ experimental vaccine contains genetic material called messenger RNA or mRNA. Importantly, the mRNA is a genetic code that tells cells what to build. In this case, an antigen may induce an immune response to the virus.
Pfizer and BioNTech are not alone when it comes to developing a coronavirus vaccine. At the moment, there are more than 100 vaccines under development based on the information provided by the World Health Organization.
For example, another company working on a coronavirus vaccine is Moderna. The vaccine created by Moderna is expected to enter a late-stage trial later this month, pending the results from its mid-stage trial. Interestingly, if all goes well, its vaccine could be available for public distribution by the end of 2020.
However, developing as well as testing and reviewing any potential vaccine is a long, expensive, and complex process. It could take years to achieve this goal. However, companies are trying to create an effective vaccine as soon as possible.